Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy

Introduction: Psoriasis significantly impacts a patient’s quality of life (QoL). Bimekizumab targets IL-17A and IL-17F, offering a broader blockade of the IL-17 pathway compared to other IL-17 inhibitors. Objectives: This study evaluated the clinical efficacy of bimekizumab in bio-naive and bio-e...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Annunziata Dattola, Nicoletta Bernardini, Elena Campione, Emanuele Amore, Simone Amato, Giacomo Caldarola, Clara De Simone, Domenico Giordano, Gaia Moretta, Vincenzo Panasiti, Gianluca Pagnanelli, Vincenzo Roberti, Ruslana Gaeta Shumak, Nevena Skroza, Ersilia Tolino, Paola Tribuzi, Salvatore Zanframundo, Luca Bianchi, Severino Persechino, Concetta Potenza, Giovanni Pellacani, Ketty Peris, Antonio Giovanni Richetta
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Mattioli1885 2025-04-01
Serie:	Dermatology Practical & Conceptual
Soggetti:	Bimekizumab, IL-17 Inhibition, Psoriatic Arthritis, IL-17, sensitives area, difficult to treat areas, psoriasis
Accesso online:	https://dpcj.org/index.php/dpc/article/view/4976
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!